|
The study by researchers at the Ohio State University ComprehensiveCancer Center -- Arthur G. James Cancer Hospital and Richard J.Solove Research Institute (OSUCCC -- James) found that whenmicroRNA-3151 (miR-3151) is overexpressed in CN-AML, the diseaseresponds poorly to treatment and patients experience shorterremissions and survival periods. This effect is independent ofother gene mutations that may be present in the cells. Additionally, miR-3151 is encoded within a gene called BAALC, whichitself is an independent marker of poor survival when overexpressedin CN-AML. The findings, published online in the journal Blood (and as a Plenary paper which represents the top 1 to 5 percent ofpapers published in the print edition of Blood ), provide new insights into the nature of AML and might in thefuture help determine the best therapy for individual patients andfurther personalize AML therapy. "Patients with high levels of both miR-3151 and BAALC had thepoorest outcome compared with those showing high expression ofeither miR-3151 or BAALC alone, or those expressing low levels ofboth," says principal investigator Dr. Clara D. Bloomfield, aDistinguished University Professor at Ohio State and cancer scholarand senior advisor to the OSUCCC -- James. "This suggests thatmiR-3151 and BAALC may act through different mechanisms to enhancepoor outcome of CN-AML patients." The study involved 179 patients aged 60 years or older with CN-AMLwho were treated on Cancer and Leukemia Group B (CALGB) clinicaltrials. MicroRNAs are small molecules that cells use to help regulate thekinds and amount of proteins they make. About one-third of humanmicroRNAs are encoded within host genes. Specifically, they arelocated in the portions of genes called introns, short stretches ofDNA that are not used when genetic information is translated tomake a protein. "Very little is known about the regulation of microRNAslocated within introns, and especially about their possibleinteractions with their host genes," says first author Dr.Ann-Kathrin Eisfeld, a post-doctoral researcher who works in thelaboratory of study co-author Dr. Albert de la Chapelle andBloomfield. "This is the first description of interplay of an oncogene andits intronic, and possibly oncogenic, microRNA," Eisfeld says."It may be the first of other important intronic microRNAs inleukemia and perhaps other malignancies." Funding from the National Cancer Institute, the Coleman LeukemiaResearch Foundation, the Deutsche Krebshilfe-Dr Mildred ScheelCancer Foundation, the Pelotonia Fellowship Program and the ConquerCancer Foundation supported this research. Other researchers involved in this study were Guido Marcucci, KatiMaharry, Sebastian Schwind, Michael D. Radmacher, Deedra Nicolet,Heiko Becker, Krzysztof Mrózek, Susan P. Whitman, Klaus H.Metzeler, Jason H. Mendler, Yue-Zhong Wu, Sandya Liyanarachchi,Ravi Patel, Michael A. Caligiuri, Stephan M. Tanner, and Albert dela Chapelle at The Ohio State University; Maria R. Baer atUniversity of Maryland; Bayard L. Powell at Wake Forest University;Thomas H. Carter at University of Iowa; Joseph O. Moore at DukeUniversity; Jonathan E. Kolitz at Hofstra North Shore-Long IslandJewish School of Medicine; Meir Wetzler at Roswell Park CancerInstitute; and Richard A. Larson at University of Chicago MedicalCenter. We are high quality suppliers, our products such as China Portable Gas Stoves , Pvc Flexible Pipes Manufacturer for oversee buyer. To know more, please visits Camping Gas Cylinders.
Related Articles -
China Portable Gas Stoves, Pvc Flexible Pipes Manufacturer,
|
